Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen

摘要: // Richard E. Kast 1 , Nicolas Skuli 2 Georg Karpel-Massler 3 Guido Frosina 4 Timothy Ryken 5 and Marc-Eric Halatsch IIAIGC Study Center, Burlington, VT, USA INSERM, Centre de Recherches en Cancerologie Toulouse, CRCT, Inserm/Universite Toulouse III, Paul Sabatier, Hubert Curien, France Department of Neurosurgery, Ulm University Hospital, Albert-Einstein-Allee, Ulm, Germany Mutagenesis & Cancer Prevention Unit, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Largo Rosanna Benzi, Genoa, Italy Kansas, Lawrence, KS, Correspondence to: Kast, email: Keywords : AMPK, EIS regimen, EMT, glioma, glioblastoma Received March 02, 2017 Accepted May 12, Published June 01, Abstract This paper outlines a treatment protocol to run alongside standard current glioblastoma- resection, temozolomide radiation. The epithelial mesenchymal transition (EMT) inhibiting sextet, Regimen, uses the ancillary attributes six older medicines impede EMT during glioblastoma. is an actively motile, therapy-resisting, low proliferation, transient state that integral feature cancers’ lethality generally specifically. It believed be glioblastoma’s centrifugal migration occurs. also untreated but enhanced by chemotherapy, radiation surgical trauma. Regimen antifungal drug itraconazole block Hedgehog signaling, antidiabetes metformin AMP kinase (AMPK), analgesic naproxen Rac1, anti-fibrosis pirfenidone transforming growth factor-beta (TGF-beta), psychiatric quetiapine receptor activator NFkB ligand (RANKL) antibiotic rifampin Wnt- all their previously established attributes. All these systems have been identified as triggers worthy targets inhibit. drugs good safety profile when used individually. They are not expected any new side effects combined. Further studies needed.